Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits
NCT ID: NCT00476346
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5201 participants
INTERVENTIONAL
2002-05-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Supplementation with calcium 2000 mg/d and vitamin D 800 IU/d will significantly reduce the incidence of stress fractures in female Navy recruits during 8 weeks of basic training.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Calcium and Vitamin D Supplementation During Marine Corps Training
NCT02636348
Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture
NCT02375503
The Effect of Vitamin D and Calcium Supplementation on the Prevention of Stress Fractures.
NCT05186194
Vitamin D3 Supplementation and Stress Fracture Occurrence in High-Risk Collegiate Athletes
NCT03395171
Optimizing Vitamin D Status During Initial Military Training
NCT01617109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: We recruited 5201 female Navy recruit volunteers and randomized them to a 2000 mg calcium and 800 IU vitamin D supplement/day or placebo. SFx were ascertained when recruits reported to the Great Lakes clinic with symptoms. All SFx were confirmed with radiography or technetium scan according to the usual Navy protocol.
Results: A total of 309 subjects were diagnosed with a SFx resulting in an incidence of 5.9% per eight weeks. Using "intention-to-treat" analysis by including all enrolled subjects, Fisher's Exact test found that the calcium and vitamin D group had a 25% lower incidence of SFx than the control group (6.6% vs 5.3%, respectively, p=0.03). The per protocol analysis, including only the 3700 recruits who completed the study, found a 27% lower incidence of fractures in the supplemented vs the control group (8.6% vs 6.8%, respectively, p=0.02).
Conclusions: Generalizing the findings to the population of 14,416 females who entered basic training at the Great Lakes during the 24 months of recruitment, calcium and vitamin D supplementation for the entire cohort would have prevented about 130 persons per year from fracturing. Such a decrease in SFx would be associated with a significant decrease in morbidity and financial costs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Calcium
Daily calcium supplementation Intervention: Calcium 2000mg / daily
Calcium & Vitamin D
Calcium 2000mg / daily Vitamin D 800IU / daily
Vitamin D
Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
Calcium & Vitamin D
Calcium 2000mg / daily Vitamin D 800IU / daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium & Vitamin D
Calcium 2000mg / daily Vitamin D 800IU / daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
United States Department of Defense
FED
Creighton University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Creighton University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joan M Lappe, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Creighton University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Creighton University
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAMD-17-01-1-0807
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.